Jeffrey Clarke, PA
Physician Assistant · Whiteville, NCNPI 1013139096
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (60.0%), speaking fees and education — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by G1 Therapeutics, Inc. at 37.4% of the total. Reporting peaked in 2021 at $1,563 and has fallen 55.9% since, to $689 in 2025. Among physician assistant clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 95 payments — averaging $42.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- G1 Therapeutics, Inc.$2K
- AstraZeneca$406
- Novo Nordisk$365
- AbbVie$266
- Astellas Pharma US Inc$158
- Lilly USA, LLC$150
- plus $1K from 21 others
Across 3 payments — averaging $4043.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$12K
What the payments were for
- Speaking & faculty fees$1,50037%
- Food & beverage$2,40760%
- Education$1073%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| G1 Therapeutics, Inc. | 1 | $1,500 |
| AstraZeneca | 5 | $406 |
| Novo Nordisk | 12 | $365 |
| AbbVie | 18 | $266 |
| Astellas Pharma US Inc | 4 | $158 |
| Lilly USA, LLC | 3 | $150 |
| Abbott | 8 | $148 |
| Paratek Pharmaceuticals, Inc. | 1 | $125 |
| Johnson & Johnson | 1 | $125 |
| Pfizer | 6 | $117 |
| Ironwood Pharmaceuticals, Inc | 1 | $100 |
| GSK | 7 | $99 |
| Phathom Pharmaceuticals, Inc. | 7 | $85 |
| Amgen | 4 | $58 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $46 |
| Ardelyx, Inc. | 3 | $46 |
| Exact Sciences | 2 | $33 |
| Insulet Corporation | 1 | $25 |
| Inspire Medical Systems, Inc. | 1 | $23 |
| Irhythm Technologies, Inc. | 1 | $23 |
| Forte Bio-pharma LLC | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| Merck | 1 | $16 |
| Viatris Specialty LLC | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Intra-sana Laboratories | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,014 in reported general payments places this provider in the 90th percentile of 7,441 physician assistant providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 227 | $227,289 |
| JanuviaSitagliptin Phosphate | 230 | $226,167 |
| JardianceEmpagliflozin | 194 | $197,084 |
| LinzessLinaclotide | 193 | $185,578 |
| OzempicSemaglutide | 107 | $137,337 |
| MounjaroTirzepatide | 106 | $120,505 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 126 | $109,817 |
| Tresiba Flextouch U-200Insulin Degludec | 55 | $86,706 |
| XareltoRivaroxaban | 82 | $72,514 |
| FarxigaDapagliflozin Propanediol | 51 | $55,636 |
| VascepaIcosapent Ethyl | 81 | $53,704 |
| TrulicityDulaglutide | 40 | $50,785 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 12 | $50,204 |
| RybelsusSemaglutide | 37 | $49,297 |
| MyrbetriqMirabegron | 71 | $40,047 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia, Janumet Xr | $16 | $234,367242 claims |
| PfizerEliquis | $117 | $227,289227 claims |
| AbbVieLinzess, Vraylar, Namzaric | $266 | $226,593229 claims |
| Novo NordiskOzempic, Rybelsus | $365 | $186,634144 claims |
| Lilly USA, LLCMounjaro, Trulicity | $150 | $171,291146 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $99 | $135,764160 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $406 | $87,38593 claims |
| Johnson & JohnsonXarelto | $125 | $72,51482 claims |
| Astellas Pharma US IncMyrbetriq | $158 | $40,04771 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $14 | $12,83018 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,441 physician assistant providers in North Carolina.
Other physician assistant in Whiteville
- Jo HughesGreensboro$814K
- Rachel HolzhauerCharlotte$739K
- Amber BlairCharlotte$551K
- Benjamin EpsteinDavidson$447K
- Rebecca KrausDavidson$425K
- Brooke JonesGoldsboro$259K
- Philip ReasbeckWilson$180K
- Katherine SchultzHuntersville$164K
- Kristin CabedaCharlotte$135K
- Jay ClarkeArden$133K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.